|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: NORLAND MEDICAL SYSTEMS INC, 10-Q, 2000-08-11 |
Next: HEMISPHERX BIOPHARMA INC, 10-K/A, 2000-08-11 |
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-END> JUN-30-2000
<CASH> 232,453
<SECURITIES> 0
<RECEIVABLES> 1,874,082
<ALLOWANCES> 301,000
<INVENTORY> 2,726,021
<CURRENT-ASSETS> 4,910,614
<PP&E> 1,078,014
<DEPRECIATION> 0
<TOTAL-ASSETS> 5,988,628
<CURRENT-LIABILITIES> 5,665,657
<BONDS> 0
0
0
<COMMON> 13,521
<OTHER-SE> (823,674)
<TOTAL-LIABILITY-AND-EQUITY> 5,988,628
<SALES> 7,825,871
<TOTAL-REVENUES> 7,825,871
<CGS> 4,323,442
<TOTAL-COSTS> 11,723,440
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 137,158
<INCOME-PRETAX> (8,353,880)
<INCOME-TAX> 4,109,841
<INCOME-CONTINUING> (12,463,721)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (12,463,721)
<EPS-BASIC> (0.47)
<EPS-DILUTED> (0.47)
</TABLE>
|
|